Brought to you by 
Lilly announces Guidant IPO for 20% of new company's stock
13 Jul 1999
Executive Summary
Eli Lilly's device spin-off, Guidant Corp. (cardiac rhythm management, coronary artery disease intervention, minimally invasive surgery) has completed its IPO of 14.26 million shares at $14.50 per share, netting $192.5 million.
Deal Industry
- Medical Devices
Deal Status
- Final
Deal Type
-
Financing
- IPO
- Spin-Off
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Lilly announces Guidant IPO for 20% of new company's stock
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice